Lite Strategy LITS
NASDAQ LITS
$0.99 +0.05 (+4.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Change in Accured Expenses (2010 - 2026)

Lite Strategy (LITS) posted quarterly Change in Accured Expenses of -$42000.0 for Q1 2026, up 93.33% year-over-year from -$21724.1 in Q1 2025, and down 125.15% quarter-over-quarter from $167000.0 in Q4 2025.

Lite Strategy (LITS) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Lite Strategy's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$42000.0 for Q1 2026.

  • In Q1 2026, Change in Accured Expenses rose 93.33% year-over-year to -$42000.0; the TTM figure through Mar 2026 stood at -$371000.0 (up 91.43% YoY), while the FY2025 annual figure was -$4.0 million, up 44.89% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at -$42000.0, down from $167000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $5.1 million in Q4 2022, with the low at -$8.2 million in Q3 2023.
  • The 5-year median for Change in Accured Expenses is -$201000.0 (2024), against an average of -$533823.5.
  • Peak annual rise in Change in Accured Expenses reached 505.05% in 2023, while the deepest fall reached 615.31% in 2023.
  • Lite Strategy's Change in Accured Expenses stood at $5.1 million in 2022, then plunged by 73.57% to $1.4 million in 2023, then sank by 115.12% to -$205000.0 in 2024, then jumped by 181.46% to $167000.0 in 2025, then slumped by 125.15% to -$42000.0 in 2026.
  • Business Quant data shows LITS's Change in Accured Expenses at -$42000.0 in Q1 2026, $167000.0 in Q4 2025, and -$613000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Lite Strategy 35.71 Mn 28.17 Mn - -42,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -42,000.00
Mar 31, 2026 -42,000.00
Dec 31, 2025 167,000.00
Dec 31, 2025 167,000.00
Sep 30, 2025 -613,000.00
Sep 30, 2025 -613,000.00
Jun 30, 2025 117,000.00
Jun 30, 2025 117,000.00
Mar 31, 2025 -630,000.00
Mar 31, 2025 -630,000.00
Dec 31, 2024 -205,000.00
Dec 31, 2024 -205,000.00
Sep 30, 2024 -3.29 Mn
Sep 30, 2024 -3.29 Mn
Jun 30, 2024 -201,000.00
Jun 30, 2024 -201,000.00
Mar 31, 2024 -257,000.00
Mar 31, 2024 -257,000.00
Dec 31, 2023 1.36 Mn
Dec 31, 2023 1.36 Mn